Sandimmune Articles
Sandoz' 1994 Sales Advance 11%
23 January 1995
SangStat To Develop Generic Ciclosporin
19 December 1994
3% Increase In Sales For Sandoz
31 October 1994
Cost Effectiveness Of Sandimmun Neoral
31 October 1994
Neoral Is An Advance Over Sandimmun
10 October 1994
New Drug Developments In Transplant Medicine
12 September 1994
SOLID VOLUME GROWTH HELPS SANDOZ' SALES
25 July 1994
CICLOSPORIN'S ROLE IN BOWEL INFLAMMATION
4 July 1994
SANDIMMUN NEORAL WELCOMED AS ADVANCE
4 April 1994
SALES UP IN 1st NINE MTHS AT SANDOZ
25 October 1993
SUSTAINABLE EARNINGS GROWTH FOR SANDOZ
16 August 1993
CICLOSPORIN AS A MICROEMULSION
8 March 1993
SANDOZ 1992 SALES SEE 8% INCREASE
1 February 1993
SANDIMMUNE GAINS NEW INDICATION IN USA
7 December 1992
NCI PROGRAM FOR ANTICANCER CLINICAL TRIALS
6 July 1992
US FDA APPROVES ABBOTT BLOOD TEST
13 April 1992
EFPIA CHALLENGES EC DRAFT ON DRUG PRICING
16 March 1992
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
